The status of estrogen receptor (ER), progesterone receptor (PR) and HER2 is critical in patients undergoing breast cancer treatment. We performed this study to evaluate the QuantiGene Reagent System as a clinical test for detecting ER, PR, and HER2 RNA levels in formalinfixed, paraffin-embedded (FFPE) tissue. Methods: The RNA levels of ER, PR and HER2 were measured using the QuantiGene2.0 assay in FFPE tissue from breast cancer patients (n=40) and compared with ER and PR immunohistochemistry results and HER2 fluorescence in situ bybridization (FISH) results. Results: When the cut-off values for ER, PR, and HER2 RNA levels were 5.0, 7.2, and 50, respectively, the sensitivity, specificity, and positive and negative predictive value of the QuantiGene 2.0 Assay were 96.6%, 90%, 96.7%, and 90%, for ER; 89. 7%, 81.8%, 92.9%, and 75% for PR; and 83.3%, 96.4%, 90.9%, and 93.1% for HER2, respectively. The Allred scores for ER and PR as well as the HER2 FISH ratio were correlated with RNA levels (p=0. 046, r=0.32; p<0.001, r=0.61; p<0.001, r=0.75, respectively). Conclusion: We demonstrated that the ER, PR, and HER2 RNA levels as measured by the QuantiGene 2.0 assay were reproducible and correlated well with immunohistochemistry and FISH results. Measuring ER, PR, and HER2 RNA levels from formalin-fixed, paraffin-embedded tissue using the QuantiGene 2.0 assay, which was a relatively simple technique easily performed in a usual laboratory, appeared to a helpful adjunct in determining the status of ER, PR, and HER2 in breast cancer.
tion to performing IHC is that it may give objective and quantitative information about ER.
The branched-chain assay QuantiGene reagent system, which is an USA Food and Drug Administration (FDA)-approved clinical diagnostic product, has been used in the US for quantitative viral load determination of HIV, hepatitis C virus and hepatitis B virus, with a detection sensitivity of <50 transcript molecules. (7) (8) (9) The QuantiGene reagent system, a sandwich nucleic acid hybridization platform in which targets are captured through cooperative hybridization of multiple probes, detects RNA directly, without either a reverse transcription step or polymerase chain reaction process. (10) It is relatively simple procedure and can be performed in a small laboratory.
Routine testing for HER2 in newly diagnosed and metastatic breast cancer cases has been recommended by the ASCO since 2001. (11, 12) The recommended test algorithm for HER2 first involves IHC, and upon a score of 2, fluorescence in situ bybridization (FISH) is used for confirmation. However, about 5% of HER2 IHC 0/1+ cases are actually HER2 amplified using the FISH test, and 5-22% of HER2 IHC 3+ cases are actually HER2 non-amplified using the FISH test. (13) (14) (15) (16) (17) (18) If there was a simple way to measure HER2 RNA levels as well as HER2 IHC, it would be useful for preventing the possible misclassification of HER2.
In the current study, we used the QuantiGene Reagent System to detect ER, PR, and HER2 RNA levels in formalin-fixed, paraffin-embedded (FFPE) tissue to evaluate its value as a clinical test.
METHODS
We evaluated 40 patients who had undergone breast 
IHC assay for ER, PR, and HER2
Sections from whole block tissues and paraffin-embedded tissue arrays were deparaffinised and rehydrated in a graded series of alcohol. Endogenous peroxidase activity was blocked using 0.3% hydrogen peroxide and the tissue arrays were processed in an automatic IHC staining machine using standard procedures (Lab Vision autostainer; Lab Vision Co., Fremont, USA) with a DAKO ChemMate TM EnVision TM system (DAKO, Carpinteria, USA).
The following antibodies were used: ER (20) and HER2 non-amplified(21)) were used as background and negative controls, respectively.
To verify that the resulting assay signals were linearly proportional to sample input, a two-fold dilution series of each sample was performed.
The RNA levels of ACTB, GUSB, and TBP were measured to normalize the RNA levels of ER, PR, and HER2.
Normalization was done in the following manner: 
Statistical analysis
All statistical analyses were performed using SPSS Table 2 ). The Allred scores for ER staining on whole sections were correlated with ER RNA levels (p=0.046, r=0.32; Figure 2A ).
The PR RNA levels ranged from 0.00 to 399.99. We considered the PR status obtained from whole sections using Allred scoring to be the gold standard. The RNA levels in cases that were PR IHC-positive were significantly higher than those cases that were PR IHC-negative Table 2 ). The Allred scores for PR staining of whole sections were correlated with PR RNA levels (p<0.001, r=0.61; Figure 2B ).
The RNA levels for HER2 ranged from 0.00 to 560.0.
We considered the HER2 FISH results to be the gold stand- Table 2 . Sensitivity, specificity, PPV, and NPV of the QuantiGene 2.0 assay for ER, PR, and HER2
for the HER2 RNA level, the QuantiGene 2.0 Assay for HER2 showed sensitivity, specificity, PPV and NPV of 83.3%, 96.4%, 90.9%, and 93.1%, respectively ( Table 2 ).
The HER2 FISH ratio was correlated with HER2 RNA levels (p=0.00, r=0.75; Figure 2C ). 
DISCUSSION

CONCLUSION
We demonstrated that ER, PR, and HER2 RNA levels as measured by the QuantiGene 2.0 assay were reproducible and that they correlated well with IHC and FISH results. Measuring ER, PR, and HER2 RNA levels using the QuantiGene 2.0 assay, which is a simple step that can be performed in most laboratories, may be a helpful adjunct in determining the status of ER, PR and HER2 in breast cancer.
